Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

MLA

Giuseppe A. Palumbo, et al. “Ruxolitinib Treatment in Myelofibrosis and Polycythemia Vera Causes Suboptimal Humoral Immune Response Following Standard and Booster Vaccination with BNT162b2 MRNA COVID-19 Vaccine.” Frontiers in Oncology, vol. 13, Feb. 2023. EBSCOhost, https://doi.org/10.3389/fonc.2023.1117815.

APA

Giuseppe A. Palumbo, Daniela Cambria, Enrico La Spina, Andrea Duminuco, Antonio Laneri, Anna Longo, Calogero Vetro, Sebastiano Giallongo, Alessandra Romano, Francesco Di Raimondo, Daniele Tibullo, & Cesarina Giallongo. (2023). Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1117815

Chicago

Giuseppe A. Palumbo, Daniela Cambria, Enrico La Spina, Andrea Duminuco, Antonio Laneri, Anna Longo, Calogero Vetro, et al. 2023. “Ruxolitinib Treatment in Myelofibrosis and Polycythemia Vera Causes Suboptimal Humoral Immune Response Following Standard and Booster Vaccination with BNT162b2 MRNA COVID-19 Vaccine.” Frontiers in Oncology 13 (February). doi:10.3389/fonc.2023.1117815.